PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results : vimarsana.com

Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase 3 Trial in Late June 2023 Total of 20 centers in U.S., Europe and Israel Expected to be Opened by End of Current Quarter Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage bio

Related Keywords

Israel , United States , Dikla Czaczkes Akselbrad , Brian Ritchie , Czaczkes Akselbrad , Nasdaq , Linkedin , Exchange Commission , European Journal Of Pharmaceutical Sciences , Company Annual Report On Form , Drug Administration , Twitter , Polypid Ltd , Reached Agreement , Abdominal Colorectal Surgical Site , Late June , Israel Expected , Call Scheduled , Corporate Highlights , European Journal , Chief Executive , Call Dial In , Webcast Information , Polymer Lipid Encapsulation , Active Pharmaceutical Ingredients , Private Securities Litigation Reform Act , Annual Report , Polypid , He Company ,